Interestingly, a recently described TRH-based compound (JAK4D), which binds to a pharmacologically different receptor (vs. the one in pituitary) in the human brain, appears to be a promising treatment for different neurodegenerative diseases, and proved to be effective in a mouse model of ALS by attenuating neuronal loss in the lumbar spinal cord [10]. The gene discussed is TRH; the disease is neurodegenerative disease.